Sign up to save your podcasts
Or
Share ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH 2025: March Biosciences reported 5 complete responses in all 5 first patients treated in the phase 2 study of its CD5 targeting CAR-T for T-cell lymphoma
Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.
View all episodes
By BiotechTV
4.3
66 ratings
Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point.
More shows like BiotechTV - News
View all
We Study Billionaires - The Investor’s Podcast Network
3,374 Listeners
Bloomberg Businessweek
426 Listeners
WSJ Tech News Briefing
1,644 Listeners
The Meb Faber Show - Better Investing
938 Listeners
The Long Run with Luke Timmerman
125 Listeners
The Readout Loud
321 Listeners
Value Investing with Legends
213 Listeners
Fiction - Comedy Fiction
6,444 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,855 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
5 Listeners
Cheeky Pint
49 Listeners